Navigation Links
Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
Date:2/12/2009

Claims extend and strengthen Odyssey Thera's coverage to include GPCR directed screening and drug profiling.

SAN RAMON, Calif., Feb. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that it has been granted a United States patent entitled "Fragment Complementation Assays for G-Protein-Coupled Receptors and their Signaling Pathways." The patent broadly covers methods for screening compounds and for identifying drug leads based on their ability to activate, inhibit or otherwise modulate G-protein-coupled receptors and the diverse signaling pathways linked to these receptors.

"This patent further extends and strengthens our deep patent estate in drug discovery and development technologies," said John K. Westwick, Ph.D., Odyssey Thera CEO and co-author on the patent. "GPCRs are among the most valued targets for drug discovery, and our proprietary technologies enable GPCR-directed drug discovery in a native biological context. The fluorescence-based assays described in this patent are the only available strategy for capturing GPCR activities, including responses of hetero-dimeric GPCR complexes and diverse downstream effector proteins, in living human cells. These powerful new tools are essential in our search for more effective therapies for cancer and other un-met medical needs."

This is the thirteenth patent issued to Odyssey Thera, and solidifies its leadership position in cellular assay and drug discovery technologies. The inventions covered by this patent (U.S. Patent No. 7,488,583) were made by Odyssey Thera scientists.

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a drug discovery company building therapeutic pipelines for oncology and other chronic diseases. Odyssey Thera's pathway-based approach centers on its proprietary protein-fragment complementation assay (PCA) technology, as well as the considerable body of trade secrets it has developed in sc
'/>"/>

SOURCE Odyssey Thera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Animal Imaging
2. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
5. Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2
... , June 25 Ruedi Waeger , Ph.D., former president ... of Directors, was honored with the Robert W. Reilly Leadership award June ... , , , ... Plasma Protein Therapeutics Association (PPTA) and recognizes individuals who exemplify the leadership qualities ...
... Beardsworth Consulting Group, Inc. announces the appointments of ... Robert W. Malone , M.D. as the company,s Medical Director, Vaccines. ... Dr. Alison Martin ... of clinical research experience.  She joins Beardsworth from the National Cancer Institute ...
... HOPKINTON, Mass. , June 25 Caliper Life ... and services for drug discovery and life sciences research, hosted its ... 9 and 10. This thought-leadership conference is focused on sharing ... process, leading to the next generation of breakthrough diagnostics and therapies. ...
Cached Biology Technology:Ruedi Waeger Receives the 2010 Robert W. Reilly Leadership Award from Plasma Protein Therapeutics Association 2Alison Martin, MD and Robert W. Malone, MD Join Beardsworth 2Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life 2Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life 3
(Date:7/24/2014)... a low vision specialist at The University of Texas ... been awarded a grant to help Harris County residents ... or surgery. , Even with corrective lenses, many people ... there are a variety of low vision devices, such ... their vision loss. , Iyer is using the three-year, ...
(Date:7/24/2014)... week for an all-day public forum on a $1.7 ... to dredge toxic sediment from an eight-mile stretch of ... the plan, which proposes removing 4.3 million cubic yards ... one of the largest cleanups in the agency,s history. ... , "We need to ensure the future well-being of ...
(Date:7/24/2014)... the United States, wildland managers often utilize the silvicultural ... (ladder fuels). These cuttings and other post-logging debris ... in order to dispose of the material. To improve ... cover all or part of the debris pile with ... in order to keep water out. A recent study ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... of Energy,s Advanced Research Projects Agency (ARPA-E) has awarded ... Carolina State University to support research into the creation ... in high-temperature environments. "Most biofuels, such as ethanol ... plants through photosynthesis. Our project would cut out the ...
... A system that allows precise targeting of radiotherapy using ... dose of radiation they administered to lung and liver cancers ... the 2nd European Lung Cancer Conference. "With this study ... have a precise system that can give information at any ...
... is available in Spanish . , Agricultural ... Research Center in Burns, Ore., are taking a careful ... high desert rangelands. Cattle share this habitat with ... the showy commotion they create during mating season. But ...
Cached Biology News:NC State wins ARPA-E grant to study extremophile production of biofuels 2ARS scientists study effects of grazing on grouse habitat 2
AedestaTM Animal Organ/Tissue Perfusion Soln....
ANTI FLAG EP CL VEC...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: